Targeting soluble epoxide hydrolase in cardiovascular diseases: from mechanistic insights to clinical translation
The cytochrome P450 monooxygenase (CYP) system is a multigene superfamily of enzymes essential for metabolizing both exogenous and endogenous compounds. CYP epoxygenases metabolize various n-3 and n-6 polyunsaturated fatty acids (PUFAs) into bioactive epoxy fatty acids (EpFAs), including arachidonic acid (AA)-derived epoxyeicosatrienoic acids (EETs), eicosapentaenoic acid (EPA)-derived epoxyeicosatetraenoic acids (EEQs), and docosahexaenoic acid (DHA)-derived epoxydocosapentaenoic acids (EDPs). These lipid mediators have emerged as important regulators of cardiovascular homeostasis. Preclinical studies indicate that EpFAs suppress inflammatory activation, promote vasodilation, preserve mitochondrial function, and attenuate fibrosis and adverse cardiac remodelling. Emerging evidence further suggests that these protective actions may also be relevant to cardiovascular aging, where mitochondrial dysfunction, chronic low-grade inflammation, and cellular senescence contribute to the progressive decline in cardiac reserve. However, the beneficial actions of EpFAs are greatly limited by their rapid hydrolysis into less active diol metabolites, mediated by soluble epoxide hydrolase (sEH). Increased sEH expression and activity have been implicated in several inflammatory cardiovascular injuries, ischaemic heart disease, heart failure (HF), and cardiovascular aging. Genetic deletion or pharmacological inhibition of sEH in preclinical studies has shown significant therapeutic effects across various cardiovascular diseases, suggesting strong potential for developing sEH inhibitors as CVD therapeutics. In this review, we summarize preclinical and clinical evidence on the roles of EpFAs and sEH targeting in CVD, with particular emphasis on inflammatory signalling, mitochondrial preservation, cellular senescence, and cell-specific cardiovascular responses. We further discuss the translational development of sEH-targeted therapeutics, including preclinical studies, the development of pharmacological inhibitors, ongoing clinical trials, and current limitations. Finally, we explore emerging concepts in epoxide-based therapeutics and propose sEH inhibition as a promising therapeutic strategy for cardiovascular aging and CVD. Overall, a better understanding of the mechanisms and translational potential of EpFAs and sEH inhibition in inflammation and cardiovascular disease will provide valuable insight for basic and clinical researchers investigating CVD.
Authors
- John M. Seubert (ORCID: https://orcid.org/0000-0003-0764-3933)
- Liye Fang (ORCID: https://orcid.org/0000-0001-7566-7916)
- Lana Bezik
- Matteo Stagliano
Institutions
- University of Alberta (CA)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fphar.2026.1989120
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Institutes of Health Research